"In the future, the incorporation of the Cre reporter system into our pipeline will allow Phylogica to rapidly validate new FPPs in vitro and to monitor systemic delivery of Cre recombinase in vivo. (Refer ASX release 2 March 2018)"
It will be interesting to see if this new system will be effective in delivering more uptake into cells once it's incorporated into their technology. I'd also like to know what other FPPs from the list highlighted in the announcement dated 05/09/17 below (i.e. FPPs 38, 49, 51, 52 and 55) are more potent at delivering cargo inside the nucleus of a specific tissue cell than the present lead candidate 1746 FPP? And when specifically they expect to go live with the CRE experiments on the live animal (in vivo) model and estimated time for completion?
I wonder why there was no specific commentary regarding the cancer peptide vaccine? I was looking forward to an update on this. Perhaps a question for the upcoming conference call.
Tony
PYC Price at posting:
3.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)